Safety findings from the final analysis of the phase 3 ARAMIS trial showed that the androgen receptor inhibitor remained well tolerated with longer treatment.
Jessica Skarzynski
Advertisement
Articles by Jessica Skarzynski
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBC
2
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
3
Choosing salvage therapy after prostate cancer focal ablation
4
SYNC-T demonstrates high bone metastasis resolution in phase 1 cohort
5
